Psychopharmacology

Psychopharmacology is the study of how drugs affect mood, thought, perception, and behaviour, and the branch of medicine that uses those drugs to treat mental illness.

17 frameworks, from 1900 to today · Mental Health · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Psychopharmacology is the study of how drugs affect mood, thought, perception, and behaviour, and the branch of medicine that uses those drugs to treat mental illness. Its central question is deceptively simple: can a chemical change the mind in a way that relieves suffering? For most of medical history the answer was sought in sedatives and stimulants that altered consciousness broadly. Only in the 1950s did drugs arrive that seemed to act on specific symptoms of specific illnesses, and with them came a new way of thinking about mental disorder as a matter of brain chemistry. That shift reshaped psychiatry, emptied and refilled its hospitals, and created an industry. It also produced a long argument, still unresolved, about whether the drugs treat the causes of mental illness or only its surface, and about how much of their apparent success belongs to the pill and how much to the belief surrounding it.

Sedatives, Stimulants, and the Pre-Modern Pharmacopoeia

Before the mid-twentieth century, psychiatry had few drugs that targeted mental illness as such. It had sedatives: bromides from the nineteenth century, then barbiturates from around 1900, which calmed agitation and induced sleep but carried a narrow margin between sedation and death and a strong liability for dependence. It had opium and its derivatives for distress1. It had stimulants, including amphetamines from the 1930s, used for depression and fatigue23. And it had lithium salts, which had been used in the nineteenth century for gout and, in a few scattered reports, for mania; the Australian psychiatrist John Cade revived interest in 1949 when he found that lithium carbonate calmed guinea pigs and then manic patients. These were blunt instruments. They changed the state of the nervous system without any clear idea of which illness they addressed, and the dominant treatments for severe mental illness remained institutional, physical, and sometimes surgical: restraint, hydrotherapy, insulin coma, and lobotomy.

Chlorpromazine and the Birth of the Antipsychotic Era

The turning point came in 1952, when the French surgeons Henri Laborit, Jean Delay, and Pierre Deniker observed that chlorpromazine, a phenothiazine compound first developed as a surgical anaesthetic adjunct, produced a peculiar calm in psychotic patients without the heavy sedation of barbiturates. Patients with hallucinations and delusions became quieter, more accessible, and sometimes less deluded. The drug was marketed in the United States as Thorazine and spread rapidly through asylums. Its significance was not only clinical. Chlorpromazine appeared to act on the symptoms of schizophrenia specifically, which suggested that schizophrenia had a specific biology. Within a few years researchers found that the drug blocked dopamine receptors in the brain, and this observation became the foundation of the dopamine hypothesis of schizophrenia: the idea that psychotic symptoms arise from excessive dopamine activity, and that blocking dopamine relieves them. The hypothesis was supported by the parallel finding that amphetamines, which increase dopamine, could provoke a psychosis resembling schizophrenia.

The antipsychotic era transformed the asylum. Large numbers of long-stay patients could now be discharged or managed outside hospital, and the movement toward deinstitutionalisation gathered pace in the 1960s and 1970s. The drugs were not curative, and their side effects were serious: the "extrapyramidal" movement disorders, including the irreversible tardive dyskinesia, that came from prolonged dopamine blockade. But they gave psychiatry its first widely effective pharmacological tool and made the brain-chemistry model of mental illness credible to a profession that had been dominated by psychoanalysis.

The Monoamine Hypothesis and the Antidepressants

A second wave of discovery followed in the late 1950s. Iproniazid, an antituberculosis drug, was found to elevate mood, and it worked by inhibiting monoamine oxidase, an enzyme that breaks down neurotransmitters45. Imipramine, a compound related to chlorpromazine, proved effective against depression without the sedation of the antipsychotics. These findings, together with the observation that reserpine (a blood-pressure drug) depleted monoamines and could cause depression, produced the monoamine hypothesis: the proposal that depression results from a deficiency of monoamines—serotonin, noradrenaline, and dopamine—in the brain, and that drugs which raise their levels relieve it. The hypothesis was a powerful organising idea. It gave depression a biological story and guided the search for better drugs.

That search produced the selective serotonin reuptake inhibitors4. The first, fluoxetine (Prozac), reached the market in 1987, followed by sertraline, paroxetine, and others. These drugs blocked the reuptake of serotonin specifically, with fewer of the side effects of the older tricyclics, and they were heavily marketed to a public newly willing to discuss depression. Their arrival coincided with a broad expansion of antidepressant prescribing, and the SSRIs became the emblem of a pharmacological approach to ordinary unhappiness as well as clinical depression. The monoamine hypothesis, meanwhile, came under strain: drugs raised monoamine levels within hours, but therapeutic benefit took weeks, and many patients did not respond at all. The simple deficiency story could not account for this, and later research turned toward downstream changes in receptor sensitivity and neural plasticity.

Lithium and the Mood Stabilisers

Lithium occupies a distinctive place. Cade's 1949 report was followed by controlled trials in the 1950s and 1960s, and by the 1970s lithium was established as the first drug with a specific preventive action in bipolar disorder, reducing both manic and depressive relapses. Its mechanism was long obscure—it affects several signalling pathways—and its narrow therapeutic window required regular blood monitoring, which limited its use. But it demonstrated that a mental illness could be managed prophylactically over years, and it became the model for the mood-stabiliser class, later joined by anticonvulsants such as valproate and carbamazepine.

Benzodiazepines and the Anxiolytic Model

Anxiety had its own pharmacological revolution. The barbiturates were dangerous, and in the late 1950s Leo Sternbach at Hoffmann-La Roche developed chlordiazepoxide, marketed in 1960 as Librium, followed by diazepam (Valium) in 1963. The benzodiazepines acted on a specific receptor site associated with the inhibitory neurotransmitter GABA, producing calm and sleep with a much wider safety margin than the barbiturates. They were prescribed in enormous quantities through the 1960s and 1970s, and the benzodiazepine receptor became one of the best-characterised sites in neuropharmacology. The subsequent recognition of dependence and withdrawal led to tighter prescribing, but the class remains in use for short-term anxiety and for specific indications.

Receptor Pharmacology and the Atypical Antipsychotics

Through the 1970s and 1980s, psychopharmacology became increasingly a science of receptors1. The identification of distinct dopamine receptor subtypes (D1 and D2, later D3–D5) and of multiple serotonin receptor families allowed drugs to be designed for particular targets. Clozapine, introduced in Europe in the 1970s, was the prototype of the "atypical" antipsychotics: it caused fewer movement side effects than the older drugs and seemed to help patients who had not responded to them, though it carried a risk of a dangerous blood disorder, agranulocytosis, requiring regular blood counts67. Its success, and that of risperidone and olanzapine in the 1990s, was attributed to a combination of dopamine and serotonin blockade, and the atypical class largely displaced the older drugs. The claim that atypicals were more effective for negative symptoms and cognition was later questioned by large comparative trials, but the class reshaped prescribing and the economics of the field.

Clinical Trials and the Evidence Problem

As the drug arsenal grew, so did the machinery for testing it. The randomised controlled trial, in which patients are assigned by chance to drug or placebo, became the standard method, and the double-blind design—neither patient nor assessor knowing who received which—was meant to remove bias. The trials that established chlorpromazine, lithium, and the antidepressants were landmarks of this method. But the method also revealed a persistent puzzle: in many antidepressant trials the drug outperformed placebo only modestly, and the placebo response itself was large and growing. This raised the question of how much of the drugs' effect was pharmacological and how much was expectation, and it fed a long-running debate about the size of the true benefit.

Anti-Psychiatry and the Critique of the Drug Model

The rise of drug treatment provoked a counter-movement. In the 1960s and 1970s, figures associated with anti-psychiatry—R8. D. Laing, David Cooper, and Thomas Szasz, though their positions differed sharply—argued that mental illness was not a brain disease to be medicated but a response to social conditions, a label applied to deviance, or a problem of living. Szasz's The Myth of Mental Illness (1961) attacked the very concept of mental illness as disease; Laing's work on schizophrenia emphasised its existential meaning. The critique was not primarily pharmacological, but it challenged the premise on which psychopharmacology rested: that mental disorders are biological entities that drugs can correct. The movement's influence on mainstream psychiatry faded, but its questions about coercion, labelling, and the limits of the medical model persisted and shaped later debates about over-prescription and patient consent.

Neuroimaging and the Search for Biomarkers

From the 1980s onward, new tools let researchers look at the living brain. Positron emission tomography and, later, functional magnetic resonance imaging allowed the measurement of receptor occupancy, blood flow, and metabolic activity in patients and in volunteers given drugs. These methods confirmed, for example, that antipsychotic doses occupying a certain proportion of D2 receptors were associated with both benefit and side effects, and they supported the idea that different illnesses involve different neural circuits. The hope was that imaging, genetics, and other biomarkers would allow treatment to be matched to the individual patient—"personalised" or "precision" psychopharmacology—rather than prescribed by trial and error. Progress has been slower than hoped: no blood test or scan yet reliably predicts which antidepressant will work for a given person, and the field still relies heavily on clinical judgment and sequential trials.

The Present: A Field of Effective but Imperfect Tools

Contemporary psychopharmacology rests on the classes built in the postwar decades: antipsychotics, antidepressants, mood stabilisers, anxiolytics, and stimulants for attention disorders. Their mechanisms are understood in far more detail than in 1952, and prescribing is guided by a large body of controlled trials and by guidelines that weigh efficacy against side effects. The monoamine hypothesis has been revised rather than abandoned, and research now focuses on glutamate, neuroplasticity, and the immune and endocrine systems as additional contributors9. Newer agents, including ketamine and its derivatives for treatment-resistant depression, have shown rapid effects that the older drugs could not, and have reopened the question of how antidepressants actually work. The field's open problems are substantial: the modest advantage of many drugs over placebo, the difficulty of predicting response, the side-effect burden of long-term treatment, and the unresolved relationship between the biology of mental illness and the social conditions in which it arises. The drugs changed what psychiatry could do; they did not settle what mental illness is.

References

  1. Psychopharmacology (Modern psychopharmacology), Wikipedia
  2. Management of attention deficit hyperactivity disorder (History), Wikipedia
  3. Stimulant, Wikipedia
  4. Anxiolytic (History), Wikipedia
  5. Monoamine oxidase inhibitor (History), Wikipedia
  6. Atypical antipsychotic (History), Wikipedia
  7. Clozapine (introduction, History), Wikipedia
  8. Anti-psychiatry, Wikipedia
  9. Pharmacology of antidepressants, Wikipedia

The frameworks of Psychopharmacology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1900-Present
  2. 1949-Present
  3. 1949-1975
  4. 1950-Present
  5. 1952-Present
  6. 1955-Present
  7. 1960-1980

    Anti-psychiatry

    Is mental illness really a brain disease?

    Fly to its tower in Nousfarer

  8. 1960-Present

    Biological psychiatry

    What brain biology underlies mental illness?

    Fly to its tower in Nousfarer

  9. 1960-Present
  10. 1960-Present
  11. 1960-Present
  12. 1970-Present
  13. 1970-Present
  14. 1985-Present
  15. 1987-2010
  16. 1989-Present
  17. 2000-Present

    Glutamate and Neuroplasticity Model

    Does neuroplasticity explain antidepressant action?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Anxiolytic and sedative-hypnotic phar…Lithium and Mood StabilizationSerendipity-based clinical psychophar…Stimulant pharmacology for ADHDNeuroleptic and antipsychotic pharmac…Randomized controlled trialAnti-psychiatryBiological psychiatryDopamine Hypothesis of SchizophreniaGABA-Benzodiazepine Anxiolytic ModelMonoamine Hypothesis of DepressionMood Stabilizer Prophylaxis ModelReceptor PharmacologyBiomarker and Precision Psychopharmac…Selective serotonin reuptake inhibitorAtypical antipsychoticGlutamate and Neuroplasticity Model

Beyond the field

Where Psychopharmacology's ideas came from in other fields, and what they led to there: the strongest 12 of 60 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Psychopharmacology is a planet in Nousfarer

Its city has a tower for each of these 17 frameworks. Land, walk in, and climb one concept at a time.

Land on Psychopharmacology

Related fields

Fields its ideas are linked to

More in Mental Health

See where Psychopharmacology sits on the Map of Human Knowledge